- About Overview
- Honors and Awards
- Facts and Figures
- Support the School
- Contact Us
- Dean’s Office
- Dean’s Office Overview
- Education Unit
- Office of Faculty Academic Affairs
- Office of Administration
- Org Chart
- Patient Care
Antibody Network partners with Celgene to develop cancer therapies
By UCSF School of Pharmacy Editorial Staff / Tue Sep 15, 2015
A new collaboration between Celgene Corp. and the Recombinant Antibody Network (RAN) will support the development of next-generation, antibody-based cancer therapies. The RAN is a consortium comprising researchers from the UCSF School of Pharmacy (UCSF Antibiome Center), the University of Chicago, and the University of Toronto.
In this first industry partnership for the RAN, Celgene agreed to pay $25 million for the option to enter into future license agreements to develop and commercialize promising therapeutic antibodies to cancer-related targets.
“The RAN consortium has developed an automated antibody-engineering pipeline that enables high-throughput generation and validation of high-performance recombinant antibodies, at an unprecedented scale,” James Wells, PhD, a founding member of the RAN and chair of the School’s Department of Pharmaceutical Chemistry, which houses the Antibiome Center.
“This is a unique opportunity to partner with a top biopharmaceutical company to exploit these capabilities on extracellular targets in the discovery and development of new therapies for treating cancer,” said Wells.
About the School: The UCSF School of Pharmacy aims to solve the most pressing health care problems and strives to ensure that each patient receives the safest, most effective treatments. Our discoveries seed the development of novel therapies, and our researchers consistently lead the nation in NIH funding. The School’s doctor of pharmacy (PharmD) degree program, with its unique emphasis on scientific thinking, prepares students to be critical thinkers and leaders in their field.